Brief: Eiger BioPharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results
09/03/2021 22:34
March 9 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* EIGER BIOPHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.58
* EIGER BIOPHARMACEUTICALS INC - PRO-FORMA CASH, CASH
EQUIVALENTS
AND INVESTMENTS OF $176.2 MILLION EXPECTED TO FUND PLANNED
OPERATIONS THROUGH Q4 2023
Source text for Eikon: ID:nPnchg17ca
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview